A statistical approach being used to support a new class of Alzheimer's drugs may lead to overstated claims about how the drugs work, according to a new study led by researchers at the Brown University School of Public Health.

Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.